Hiv-1 integrase derived stimulatory peptides interfering with integrase -- rev protein binding
AssigneeYissum Research Development Company of the Hebrew University of Jerusalem
InventorsAviad Levin, Zvi Hayouka, Assaf Friedler, Abraham Loyter
Life of this patent
Estimating the term…
Abstract
Isolated peptides comprising sequences derived from the protein integrase of HIV-1, as well as their analogs, mixtures, conjugates with permeability enhancing moieties, and pharmaceutical compositions are disclosed. The peptides and compositions are capable of selectively killing HIV-1 infected cells and are used in treatment of HIV infection and AIDS.
Claims38
A pharmaceutical composition comprising at least two peptides of 8-25 amino acids, or analogs, derivatives or mimetics thereof, each peptide comprising a sequence of at least 6 amino acids derived from human HIV-1 integrase (IN) protein, wherein the two peptides are derived from two different IN regions selected from the group consisting of:
- residues 118-128 (GSNFTSTTVKA SEQ ID NO:2), residues 174-188 (TAVQMAVFIHNFKRK SEQ ID NO:3);
- and residues 66-80 (THLEGKIILVAVHVA SEQ ID NO:4).
(canceled)
(Canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A synthetic or recombinant peptide of 8-25 amino acids comprising a sequence selected from the group consisting of:
- residues 118-128 (GSNFTSTTVKA SEQ ID NO:2);
- residues 174-188 (TAVQMAVFIHNFKRK SEQ ID NO:3);
- and residues 66-80 (THLEGKIILVAVHVA SEQ ID NO:4), further comprising a permeability enhancing moiety.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.